Retatrutide calculators

Retatrutide is an investigational synthetic peptide that activates three incretin and metabolic receptors at once — GIP, GLP-1, and glucagon. It is the next-generation extension of the dual-agonist concept that tirzepatide pioneered, and it is currently the subject of pharmaceutical clinical trials.

Because retatrutide has not been approved as a finished pharmaceutical at the time of writing, it is encountered almost exclusively as a lyophilized research-grade peptide in milligram-rated vials. Common vial sizes in the research market range from 5 mg to 20 mg or larger.

Like the other long-acting incretin peptides on this site, retatrutide is typically logged on a once-weekly cadence. The weekly rhythm shapes how vials are reconstituted, how doses escalate over time, and how vial duration is estimated for refill planning.

Retatrutide binds to the GIP, GLP-1, and glucagon receptors. The first two are familiar from semaglutide and tirzepatide; the addition of glucagon-receptor activation is what differentiates retatrutide from those earlier peptides and is the focus of much of its ongoing clinical research.

Triple-receptor activation produces metabolic effects that are still being characterized in published trials. Anyone tracking retatrutide in a personal log should pair the dose history with weekly metrics like weight, hunger ratings, and side-effect notes — that pairing is what turns a list of injections into a usable trend.

The compound's pharmacology is defined by its activity as a single-molecule agonist for the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. While co-activation of GLP-1 and GIP receptors is also the mechanism of tirzepatide, the addition of the glucagon receptor agonist component is what makes retatrutide a distinct investigational agent. In metabolic physiology, glucagon signaling is traditionally associated with stimulating the liver to produce glucose. However, researchers are studying how its concurrent activation with potent incretin mimetics like GLP-1 and GIP might influence energy expenditure, lipid metabolism, and appetite signaling in ways that are distinct from single- or dual-agonist peptides.

Once-weekly subcutaneous injection is the default cadence in most retatrutide logs. Each draw is small enough that a U-100 insulin syringe is the standard tool — the volumes involved are too small to read accurately on a tuberculin syringe.

Because retatrutide is potent at small milligram counts, dose escalation tends to be gradual and well-tracked. The exact week and unit count of each step is the kind of information that is hard to reconstruct from memory months later, which is why a structured dose log is more durable than scattered notes.

Dosing schedules documented in published Phase 2 clinical trials for retatrutide have involved a notably steep titration. Study protocols have detailed starting doses that escalate at predetermined intervals to much higher terminal doses than those typical for related peptides. For example, a documented titration schedule involved monthly escalations from a starting dose, progressing through tiers such as 2 mg, 4 mg, 8 mg, and up to a 12 mg maximum dose, all administered on a weekly cadence. For personal tracking, these published trial schedules are the only available structural reference points for logging dose escalation over a period of months.